OKYO (OKYO Pharma Limited Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by OKYO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | GARY S JACOB | CHIEF DEVELOPMENT OFFICER | Buy | — | — |
| 2026-08-07 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2026-08-07 | JOHN P BRANCACCIO | Director | Buy | — | — |
| 2026-08-07 | Rajkumar V. Patil | Chief Scientific Officer | Buy | — | — |
| 2026-08-07 | GABRIELE M CERRONE | Director | Buy | — | — |
| 2026-08-07 | Flavio Mantelli | CHIEF MEDICAL OFFICER | Buy | — | — |
| 2026-08-07 | GABRIELE M CERRONE | Director | Buy | — | — |
| 2026-08-07 | GARY S JACOB | CHIEF DEVELOPMENT OFFICER | Buy | — | — |
| 2026-08-07 | Rajkumar V. Patil | Chief Scientific Officer | Buy | — | — |
| 2026-08-07 | Flavio Mantelli | CHIEF MEDICAL OFFICER | Buy | — | — |
| 2026-08-07 | GABRIELE M CERRONE | Director | Buy | — | — |
| 2026-08-07 | GABRIELE M CERRONE | Director | Buy | — | — |
| 2026-08-07 | JOHN P BRANCACCIO | Director | Buy | — | — |
| 2026-08-07 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2026-07-29 | Rajkumar V. Patil | Chief Scientific Officer | A | — | — |
| 2026-07-23 | GARY S JACOB | CHIEF DEVELOPMENT OFFICER | A | — | — |
| 2026-07-23 | GABRIELE M CERRONE | Director | A | — | — |
| 2026-07-23 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-07-23 | JOHN P BRANCACCIO | Director | A | — | — |
| 2026-07-22 | Flavio Mantelli | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-07-21 | GABRIELE M CERRONE | Director | A | — | — |
| 2026-06-10 | GABRIELE M CERRONE | Director | A | — | — |
| 2026-06-10 | Willy Jules Simon | Director | A | — | — |
| 2026-06-10 | JOHN P BRANCACCIO | Director | A | — | — |
| 2026-06-10 | Keeren Rameshchandra Shah | Chief Financial Officer | A | — | — |
| 2026-06-10 | Bernard Denoyer | Director | A | — | — |
| 2023-10-31 | GABRIELE M CERRONE | Executive Chairman | J | — | — |
| 2023-09-28 | JOHN P BRANCACCIO | Director | Buy | — | — |
| 2022-05-20 | GABRIELE M CERRONE | Executive Chairman | Buy | — | — |
| 2022-05-19 | GABRIELE M CERRONE | Non-Executive Chairman | Buy | — | — |
| 2022-05-19 | GARY S JACOB | Chief Executive Officer | Buy | — | — |
| 2022-05-18 | GABRIELE M CERRONE | Non-Executive Chairman | Buy | — | — |
| 2022-05-18 | GABRIELE M CERRONE | Non-Executive Chairman | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 10,851,416 | — |
| — | CHIEF DEVELOPMENT OFFICER | 112,420 | — |
| — | Director | 35,201 | — |
| — | Chief Scientific Officer | 20,030 | — |
| — | CHIEF MEDICAL OFFICER | 20,000 | — |
| — | CHIEF EXECUTIVE OFFICER | 15,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OKYO quote page; the site-wide leaderboard is on the insider transactions hub.